After floating between small gains and losses at midday, U.S. Stocks concluded Monday’s jerky trading session with small gains, as returns in energy companies obscured a plummet in technology shares as shareholders considered possible fallout from Greek elections.
The left-wing viewpoint holders, anti-bailout Syriza party succeeded decisively in Greek parliamentary elections on Sunday, after running a campaign likely-looking to take on Greece’s international lenders and lead to an end to austerity measures. While the United States has limited direct manifestation to Greece’s comparatively small economy, unmitigated volatility in the region could hurt multinational companies.
S&P 500 SPX, +0.26% ended 5.24 points, or 0.3%, higher at 2,057.07.
The Dow Jones Industrial Average DJIA, +0.03% added 6.1 points to 17,678.70.
The NASDAQ COMP, +0.29% ended the day up 13.88 points, or 0.3%, at 4,771.76.
The yield on the 10-year Treasury climbed to 1.82 percent from 1.80 percent late Friday. About 6.2 billion shares changed hands on U.S. exchanges recently during Monday’s trading session, 7 percent below the three-month average.
Health Care SPDR (XLV), iShares Dow Jones US Healthcare (IYH) and Vanguard Health Care ETF (VHT) were in positive territory. Meanwhile, Biotech ETF iShares NASDAQ Biotechnology Index (IBB) was up 1.82%.
In April, in the course of concern, assessments had become overextended, the Nasdaq 100 fell the most in two years as investors shifted money out of Internet and biotechnology stocks and privileged companies with stable dividends and earnings. The index also sold off 8.2 percent over a one-month period starting in September amid growing concern of an international economic slowdown.
During Monday’s trading session, Biotechnology, bullied, and gold stocks also turned in strong performances on the day, while computer hardware stocks saw noteworthy weakness.
In biotech sector, Curis, Inc. (NASDAQ:CRIS), showed a leading gain of 16.17%, and closed at $1.94, attaining volume of about $2,057,646, after a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, and Aurigene Discovery Technologies Limited, a specialized, discovery stage biotechnology company developing novel therapies to treat cancer and inflammatory diseases, recently declared that they have reached an exclusive partnership contract focused on immuno-oncology and designated precision oncology targets. The partnership offers for inclusion of multiple programs, with Curis having the option to exclusively license compounds once a development candidate is nominated within each respective program.
Synthetic Biologics Inc. (NYSE:SYN), skyrocketed 13.73% to $1.74, after Jeffrey Riley, CEO, presented at the Biotech Showcase™ 2015 Conference on Tuesday, January 13, 2015, at Parc 55 Wyndham San Francisco Union Square Hotel - Room: Mission II (4th Floor).
Synthetic Biologics Inc. (NYSE:SYN), is a clinical-stage biotechnology company developing pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome.
Ampio Pharmaceuticals, Inc. (NYSE:AMPE), soared 12.47%, holding market capitalization of $276.49M, following the news that Ampio’s subsidiary Luoxis Diagnostics, Inc., declared it has secured long-term contracts with European distributors Eurobio, Una Health Limited, and THP Medical, to offer Luoxis’ RedoxSYS™ Diagnostic System to prominent academic and pharma-based research centers within their respective territories. RedoxSYS is a first-in-class diagnostic platform and robust research tool capable of measuring oxidation-reduction potential (ORP) in the body in response to injury, illness, or stress.
Ampio Pharmaceuticals, Inc. (NYSE:AMPE), is a development stage biopharmaceutical company primarily focused on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options.
ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP), inclined sharply by 10.50%, closing at $8.00, as Intrexon Corporation (XON), a leader in synthetic biology and its oncology partner, recently declared a broad exclusive licensing contract with The University of Texas MD Anderson Cancer Center, counting an exclusive sublicensing contract through MD Anderson for intellectual property developed at the University of Minnesota for the development of non-viral adoptive cellular cancer immunotherapies.
ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP), is a Boston, Massachusetts-based biotechnology company employing novel gene expression and control technology to deliver DNA for the treatment of cancer.
Juno Therapeutics Inc. (NASDAQ:JUNO), climbed 9.90% to $45.39. During Monday’s trading session, the company hits a new 52-week low of $39.31. The company opened its last trading session at $40.22, gaining volume of $2,357,850, as compared to its average trading volume of $2,814,820.
Juno Therapeutics Inc. (NASDAQ:JUNO), a biopharmaceutical company, engages in developing cell-based cancer immunotherapies. The company develops cell-based cancer immunotherapies based on its chimeric antigen receptor and T cell receptor technologies to genetically engineer T cells to recognize and kill cancer cells. Its clinical CD19 product candidates comprise JCAR015 that is in Phase I clinical trials for adult patients with relapsed/refractory B cell acute lymphoblastic leukemia (r/r ALL); JCAR017, which is in Phase I/II trials for pediatric patients with r/r ALL whose cancer has recurred after a bone marrow transplant; and JCAR014 that is in Phase I/II trials to treat various B cell malignancies in patients relapsed or refractory to standard therapies.
